Eliana Merle
Stock Analyst at UBS
(1.85)
# 2,865
Out of 4,814 analysts
75
Total ratings
30.91%
Success rate
-8.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $109 → $113 | $58.68 | +92.57% | 2 | Feb 20, 2025 | |
| MRNA Moderna | Maintains: Buy | $96 → $78 | $25.13 | +210.39% | 6 | Feb 19, 2025 | |
| ETNB 89bio | Maintains: Buy | $25 → $38 | $6.26 | +507.03% | 3 | Jan 31, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $42 → $109 | $37.79 | +188.44% | 4 | Jan 31, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Neutral | $5 → $2.2 | $1.37 | +60.58% | 4 | Jan 28, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $65 → $71 | $36.58 | +94.10% | 2 | Jan 8, 2025 | |
| ASND Ascendis Pharma | Initiates: Buy | $196 | $161.15 | +21.63% | 1 | Jan 7, 2025 | |
| TYRA Tyra Biosciences | Initiates: Buy | $28 | $9.06 | +209.05% | 1 | Jan 7, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $12 | $2.41 | +398.96% | 1 | Nov 12, 2024 | |
| IVA Inventiva | Initiates: Neutral | $3 | $3.61 | -16.90% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $4.80 | +442.23% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $74 | $27.13 | +172.81% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $411 → $441 | $295.79 | +49.09% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $20.60 | +60.19% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $101.88 | +28.59% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $2 | $0.78 | +156.34% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $83 | $18.04 | +360.09% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $253 → $288 | $232.96 | +23.63% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $33.52 | +40.21% | 2 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $3.20 | +56.25% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $2.72 | +561.76% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $13.37 | +214.14% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 | $3.21 | +460.75% | 1 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $0.81 | +884.01% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.47 | +392.17% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $6.67 | +605.18% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $6.71 | +138.45% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $123 | $8.75 | +1,305.71% | 3 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $24.64 | +443.83% | 3 | Aug 19, 2020 |
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Buy
Price Target: $109 → $113
Current: $58.68
Upside: +92.57%
Moderna
Feb 19, 2025
Maintains: Buy
Price Target: $96 → $78
Current: $25.13
Upside: +210.39%
89bio
Jan 31, 2025
Maintains: Buy
Price Target: $25 → $38
Current: $6.26
Upside: +507.03%
Akero Therapeutics
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $37.79
Upside: +188.44%
Zentalis Pharmaceuticals
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.37
Upside: +60.58%
Revolution Medicines
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $36.58
Upside: +94.10%
Ascendis Pharma
Jan 7, 2025
Initiates: Buy
Price Target: $196
Current: $161.15
Upside: +21.63%
Tyra Biosciences
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $9.06
Upside: +209.05%
Sagimet Biosciences
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $2.41
Upside: +398.96%
Inventiva
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $3.61
Upside: -16.90%
Nov 12, 2024
Initiates: Buy
Price Target: $26
Current: $4.80
Upside: +442.23%
Nov 4, 2024
Maintains: Buy
Price Target: $80 → $74
Current: $27.13
Upside: +172.81%
Nov 1, 2024
Maintains: Buy
Price Target: $411 → $441
Current: $295.79
Upside: +49.09%
Oct 30, 2024
Maintains: Neutral
Price Target: $23 → $33
Current: $20.60
Upside: +60.19%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $101.88
Upside: +28.59%
Sep 9, 2024
Maintains: Neutral
Price Target: $10 → $2
Current: $0.78
Upside: +156.34%
Aug 9, 2024
Maintains: Buy
Price Target: $85 → $83
Current: $18.04
Upside: +360.09%
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $232.96
Upside: +23.63%
May 28, 2024
Maintains: Buy
Price Target: $51 → $47
Current: $33.52
Upside: +40.21%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $3.20
Upside: +56.25%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $2.72
Upside: +561.76%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $13.37
Upside: +214.14%
Jan 19, 2023
Upgrades: Buy
Price Target: $18
Current: $3.21
Upside: +460.75%
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $0.81
Upside: +884.01%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $4.47
Upside: +392.17%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $6.67
Upside: +605.18%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $6.71
Upside: +138.45%
May 21, 2021
Initiates: Buy
Price Target: $123
Current: $8.75
Upside: +1,305.71%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $24.64
Upside: +443.83%